Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Relay Therapeutics Inc
(NQ:
RLAY
)
6.210
-0.530 (-7.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relay Therapeutics Inc
< Previous
1
2
Next >
Relay Therapeutics to Participate in Upcoming Investor Conferences
April 11, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
February 26, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
February 22, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
February 15, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces $30 Million Private Placement Financing
January 08, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 07, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 02, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
October 26, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
October 12, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 08, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
August 01, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END
Via
FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
May 25, 2023
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 24, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
May 04, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
April 27, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
April 19, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
April 18, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
March 24, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs...
Via
FinancialNewsMedia
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
March 06, 2023
Relay Therapeutics to host conference call following AACR presentation
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
March 01, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 23, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 16, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 02, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
November 07, 2022
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.